+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Comprehensive analysis of published phase I/II clinical trials between 1990-2010 in osteosarcoma and Ewing sarcoma confirms limited outcomes and need for translational investment

Comprehensive analysis of published phase I/II clinical trials between 1990-2010 in osteosarcoma and Ewing sarcoma confirms limited outcomes and need for translational investment

Clinical Sarcoma Research 2(1): 5

High grade primary bone sarcomas are rare cancers that affect mostly children and young adults. Osteosarcoma and Ewing sarcoma are the most common histological subtypes in this age group, with current multimodality treatment strategies achieving 55-70% overall survival. As there remains an urgent need to develop new therapeutic interventions, we have reviewed published phase I/II trials that have been reported for osteosarcoma and Ewing sarcoma in the last twenty years. We conducted a literature search for clinical trials between 1990 and 2010, either for trials enrolling bone sarcoma patients as part of a general sarcoma indication or trials specifically in osteosarcoma and Ewing sarcoma. We identified 42 clinical trials that fulfilled our search criteria for general sarcoma that enrolled these patient groups, and eight and twenty specific trials for Ewing and osteosarcoma patients, respectively. For the phase I trials which enrolled different tumour types our results were incomplete, because the sarcoma patients were not mentioned in the PubMed abstract. A total of 3,736 sarcoma patients were included in these trials over this period, 1,114 for osteosarcoma and 1,263 for Ewing sarcoma. As a proportion of the worldwide disease burden over this period, these numbers reflect a very small percentage of the potential patient recruitment, approximately 0.6% for Ewing sarcoma and 0.2% for osteosarcoma. However, these data show an increase in recent activity overall and suggest there is still much room for improvement in the current trial development structures. Lack of resources and commercial investment will inevitably limit opportunity to develop sufficiently rapid improvements in clinical outcomes. International collaboration exists in many well founded co-operative groups for phase III trials, but progress may be more effective if there were also more investment of molecular and translational research into disease focused phase I/II clinical trials. Examples of new models for early translational and early phase trial collaboration include the European based EuroBoNeT network, the Sarcoma Alliance for Research through Collaboration network (SARC) and the new European collaborative translational trial network, EuroSarc.

Please choose payment method:

(PDF emailed within 0-6 h: $19.90)

Accession: 052269862

Download citation: RISBibTeXText

PMID: 22587841

DOI: 10.1186/2045-3329-2-5

Related references

Analysis of phase II methodologies for single-arm clinical trials with multiple endpoints in rare cancers: An example in Ewing's sarcoma. Statistical Methods in Medical Research 27(5): 1451-1463, 2016

Prognostic determinants and treatment outcomes analysis of osteosarcoma and Ewing sarcoma of the spine. Spine Journal 17(5): 645-655, 2016

A phase II study of clinical activity of SCH 717454 (robatumumab) in patients with relapsed osteosarcoma and Ewing sarcoma. Pediatric Blood and Cancer 63(10): 1761-1770, 2017

Preclinical analysis of tasidotin HCl in Ewing's sarcoma, rhabdomyosarcoma, synovial sarcoma, and osteosarcoma. Clinical Cancer Research 13(18 Pt 1): 5446-5454, 2007

Demographic Analysis of Patients with Osteosarcoma, Chonddrosarcoma, Ewing's Sarcoma from one Sarcoma Center in Switzerland. Praxis 104(13): 673-680, 2015

Clinical outcomes and prognostic factors of Ewing sarcoma: a clinical analysis of 12 patients in Taiwan. Journal of the Chinese Medical Association 75(1): 16-20, 2012

Second-line treatment in advanced pancreatic cancer: a comprehensive analysis of published clinical trials. Annals of Oncology 24(8): 1972-1979, 2014

Survival outcomes of pediatric osteosarcoma and Ewing's sarcoma: a comparison of surgery type within the SEER database, 1988-2007. Journal of Registry Management 38(3): 153-161, 2012

Initial symptoms and clinical features in osteosarcoma and Ewing sarcoma. Journal of Bone and Joint Surgery. American Volume 82(5): 667-674, 2000

The role of basic research in clinical treatment of Ewing's sarcoma and osteosarcoma. La Chirurgia Degli Organi di Movimento 88(2): 201-209, 2004

Randomized controlled drug trials on very elderly subjects: descriptive and methodological analysis of trials published between 1990 and 2002 and comparison with trials on adults. Journals of Gerontology. Series A, Biological Sciences and Medical Sciences 60(3): 340-344, 2005

Treatment outcomes of Japanese patients with Ewing sarcoma: differences between skeletal and extraskeletal Ewing sarcoma. Japanese Journal of Clinical Oncology 46(6): 522-528, 2017

Meta-analysis of all available published clinical trials (1958-1990) on thrombolytic therapy for AMI: Relative efficacy of different therapeutic strategies. Fibrinolysis 8(2): 67-86, 1994

Phase II study of sequential gemcitabine followed by docetaxel for recurrent Ewing sarcoma, osteosarcoma, or unresectable or locally recurrent chondrosarcoma: results of Sarcoma Alliance for Research Through Collaboration Study 003. Oncologist 17(3): 321-321, 2012